Comparative Pharmacology
Head-to-head clinical analysis: TRIACET versus TRIACIN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIACET versus TRIACIN C.
TRIACET vs TRIACIN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triacetin is a triester of glycerol and acetic acid. Its exact mechanism of action is not fully understood, but it exhibits antifungal activity by disrupting fungal cell membrane integrity and inhibiting fungal growth.
TRIACIN-C is a combination of triamcinolone (a corticosteroid) and nystatin (an antifungal). Triamcinolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Nystatin binds to ergosterol in fungal cell membranes, causing pore formation and cell death.
0.5-1 mg orally three times daily; maximum dose 4 mg/day.
5 mg orally twice daily, taken with meals to enhance absorption.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5–4 hours in adults with normal renal function; may be prolonged (up to 6–8 hours) in patients with hepatic impairment.
Terminal elimination half-life: 7–9 hours. In patients with severe hepatic impairment (Child-Pugh C), half-life may extend to 15 hours; dosing adjustment recommended.
Renal, unchanged drug: <1% of dose; metabolites: approximately 20% in urine, remainder in feces via biliary elimination.
Renal: ~60% as unchanged drug; hepatic metabolism accounts for ~25% (primarily via CYP3A4), with biliary excretion of metabolites (~15%); fecal elimination <5%.
Category C
Category C
Corticosteroid
Corticosteroid